17 October 2019 | News
The MIMIX smart release patch technology has demonstrated the capacity to enhance the efficacy of commercially available, FDA-approved influenza vaccines
image credit- asianmag.com
South Korea headquartered GC Pharma, a leading manufacturer of influenza vaccines with a global reach, and US based Vaxess, an innovative biotechnology company developing the MIMIX smart release patch, have partnered to commercialize a highly effective, painless, and refrigeration-free flu vaccine in a new, convenient patch format.
The MIMIX smart release patch technology has demonstrated the capacity to enhance the efficacy of commercially available, FDA-approved influenza vaccines, as well as ease the distribution and administration to patients. The MIMIX smart release patch strengthens responses against both vaccine-included and drifted influenza strains through the use of sustained antigen presentation. This more accurately mimics a natural infection, thereby driving stronger, broader, and more durable HAI titers and influenza-specific T-cell responses. Moreover, immunization via the shelf-stable MIMIX patch simplifies delivery, patient administration, and compliance. Combining the GC Pharma influenza vaccine and Vaxess smart release patch technology creates a powerful partnership to commercialize a more effective vaccine that can be easily administered to everyone.
This partnership announcement comes just a few months after Vaxess announced a financing round led by The Engine and receipt of federal grant support for the development of the MIMIX flu smart release patch. Financial terms of the agreement were not disclosed.